Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats

Neuroscience

Volumn 169, Issue 4, 2010, Pages 1860-1871

  Oe, T ^a   Tsukamoto, M ^a   Nagakura, Y ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Biogenic amine metabolites; Biphasic response; Dopamine; Noradrenaline; Serotonin; Tetrabenazine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; NORADRENALIN; RESERPINE; SEROTONIN; TETRABENAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLD; CONTROLLED STUDY; DRUG ACTIVITY; HEAT; MALE; METABOLITE; NOCICEPTION; NONHUMAN; PREFRONTAL CORTEX; PRESSURE; PRIORITY JOURNAL; RAT; SPINAL CORD; STIMULUS RESPONSE; TACTILE STIMULATION; THALAMUS;

EID: 77955427708     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.06.061     Document Type: Article

References (51)

1. Akil H., Liebeskind J.C. Monoaminergic mechanisms of stimulation-produced analgesia. Brain Res 1975, 94:279-296.
2. Almgren O., Snider S.R., Carlsson A. Recovery of dopamine in peripheral adrenergic nerves after reserpine treatment. Naunyn Schmiedebergs Arch Pharmacol 1976, 292:133-136.
3. Basbaum A.I., Fields H.L. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 1978, 4:451-462.
4. Berge O.G., Hole K., Ogren S.O. Attenuation of morphine-induced analgesia by p-chlorophenylalanine and p-chloroamphetamine: test-dependent effects and evidence for brainstem 5-hydroxytryptamine involvement. Brain Res 1983, 271:51-64.
5. Bodnar R.J., Kordower J.H., Reches A., Wallace M.M., Fahn S. Reductions in pain thresholds and morphine analgesia following intracerebroventricular parachlorophenylalanine. Pharmacol Biochem Behav 1984, 21:79-84.
6. Borsook D., Moulton E.A., Tully S., Schmahmann J.D., Becerra L. Human cerebellar responses to brush and heat stimuli in healthy and neuropathic pain subjects. Cerebellum 2008, 7:252-272.
7. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 1973, 185:560-571.
8. Cardenas C.G., Mar L.P., Vysokanov A.V., Arnold P.B., Cardenas L.M., Surmeier D.J., Scroggs R.S. Serotonergic modulation of hyperpolarization-activated current in acutely isolated rat dorsal root ganglion neurons. J Physiol 1999, 518:507-523.
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
10. Charbit A.R., Akerman S., Goadsby P.J. Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex. J Pharmacol Exp Ther 2009, 331:752-763.
11. Choi Y., Yoon Y.W., Na H.S., Kim S.H., Chung J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994, 59:369-376.
12. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987, 26:1431-1440.
13. Dickenson A.H., Rivot J.P., Chaouch A., Besson J.M., Le Bars D. Diffuse noxious inhibitory controls (DNIC) in the rat with or without pCPA pretreatment. Brain Res 1981, 216:313-321.
14. Ehrström M., Pequignot J., Pequignot J.M., Lagercrantz H. Cooling and asphyxia differentially affect augmented noradrenaline turnover in the brain of the externalized rat foetus. Acta Physiol Scand 1998, 163:385-389.
15. Fujimiya M., Okumiya K., Yamane T., Maeda T. Distribution of serotonin-immunoreactive nerve cells and fibers in the rat gastrointestinal tract. Histochem Cell Biol 1997, 107:105-114.
16. Gassner M., Ruscheweyh R., Sandkühler J. Direct excitation of spinal GABAergic interneurons by noradrenaline. Pain 2009, 145:204-210.
17. Gobbi M., Valle F.D., Ciapparelli C., Diomede L., Morazzoni P., Verotta L., Caccia S., Cervo L., Mennini T. Hypericum perforatum Lextract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:262-269.
18. + current in nociceptors. Proc Natl Acad Sci U S A 1996, 93:1108-1112.
19. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
20. Henderson L.A., Bandler R., Gandevia S.C., Macefield V.G. Distinct forebrain activity patterns during deep versus superficial pain. Pain 2006, 120:286-296.
21. Heslop K.E., Curzon G. Depletion and repletion of cortical tissue and dialysate 5-HT after reserpine. Neuropharmacology 1994, 33:567-573.
22. Holz G.G., Shefner S.A., Anderson E.G. Serotonin depolarizes type A and C primary afferents: an intracellular study in bullfrog dorsal root ganglion. Brain Res 1985, 327:71-79.
23. Horiuchi H., Ogata T., Morino T., Takeba J., Yamamoto H. Serotonergic signaling inhibits hyperalgesia induced by spinal cord damage. Brain Res 2003, 963:312-320.
24. Ireland S.J., Jordan C.C. Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion. Br J Pharmacol 1987, 92:417-427.
25. Jääskeläinen S.K., Rinne J.O., Forssell H., Tenovuo O., Kaasinen V., Sonninen P., Bergman J. Role of the dopaminergic system in chronic pain-a fluorodopa-PET study. Pain 2001, 90:257-260.
26. Jaber M., Fournier M.C., Bloch B. Reserpine treatment stimulates enkephalin and D2 dopamine receptor gene expression in the rat striatum. Brain Res Mol Brain Res 1992, 15:189-194.
27. Jasmin L., Boudah A., Ohara P.T. Long-term effects of decreased noradrenergic central nervous system innervation on pain behavior and opioid antinociception. J Comp Neurol 2003, 460:38-55.
28. Jensen T.S., Smith D.F. Role of 5-HT and NA in spinal dopaminergic analgesia. Eur J Pharmacol 1982, 86:65-70.
29. Kulkarni S.K., Robert R.K. Reversal by serotonergic agents of reserpine-induced hyperalgesia in rats. Eur J Pharmacol 1982, 83:325-328.
30. Lu Y., Perl E.R. Selective action of noradrenaline and serotonin on neurones of the spinal superficial dorsal horn in the rat. J Physiol 2007, 582:127-136.
31. Martínez-Olivares R., Villanueva I., Racotta R., Piñón M. Depletion and recovery of catecholamines in several organs of rats treated with reserpine. Auton Neurosci 2006, 128:64-69.
32. Matsumoto K., Mizowaki M., Suchitra T., Murakami Y., Takayama H., Sakai S., Aimi N., Watanabe H. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 1996, 317:75-81.
33. Mehvar R., Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987, 76:461-465.
34. Nagakura Y., Oe T., Aoki T., Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 2009, 146:26-33.
35. Nammi S., Boini K.M., Koppula S., Sreemantula S. Reserpine-induced central effects: pharmacological evidence for the lack of central effects of reserpine methiodide. Can J Physiol Pharmacol 2005, 83:509-515.
36. Penttilä A. The effect of reserpine on the regional 5-hydroxytryptamine content of the rat gastrointestinal tract. Ann Med Exp Biol Fenn 1969, 47:99-104.
37. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 2006, 80:53-83.
38. Ponzio F., Achilli G., Calderini G., Ferretti P., Perego C., Toffano G., Algeri S. Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine. Neurobiol Aging 1984, 5:101-104.
39. Potvin S., Grignon S., Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009, 63:390-402.
40. Reddy S.V., Yaksh T.L. Spinal noradrenergic terminal system mediates antinociception. Brain Res 1980, 189:391-401.
41. Ribas C., Miralles A., Busquets X., García-Sevilla J.A. Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA. Br J Pharmacol 2001, 132:1467-1476.
42. Roffler-Tarlov S., Sharman D.F., Tegerdine P. 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the mouse striatum: a reflection of intra- and extra-neuronal metabolism of dopamine?. Br J Pharmacol 1971, 42:343-351.
43. Roz N., Rehavi M. Hyperforin depletes synaptic vesicles content and induces compartmental redistribution of nerve ending monoamines. Life Sci 2004, 75:2841-2850.
44. Russell I.J., Vaeroy H., Javors M., Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
45. Schäfers M., Sorkin L.S., Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 2003, 104:579-588.
46. Seifert F., Jungfer I., Schmelz M., Maihöfner C. Representation of UV-B-induced thermal and mechanical hyperalgesia in the human brain: a functional MRI study. Hum Brain Mapp 2008, 29:1327-1342.
47. Steinman J.L., Carlton S.M., Haber B., Willis W.D. Differential effects of p-chlorophenylalanine on indoleamines in brainstem nuclei and spinal cord of rats. I. Biochemical and behavioral analysis. Brain Res 1987, 426:297-309.
48. Todorovic S., Anderson E.G. Serotonin preferentially hyperpolarizes capsaicin-sensitive C type sensory neurons by activating 5-HT1A receptors. Brain Res 1992, 585:212-218.
49. 2-autoreceptors. Naunyn Schmiedebergs Arch Pharmacol 1994, 349:25-33.
50. Wood P.B. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004, 62:420-424.
51. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008, 8:781-797.